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Abstract of the Dissertation
The Role of Histidine Rich Protein II in Cerebral Malaria Pathogenesis
By
Priya Pal
Doctor of Philosophy in Biology and Biomedical Sciences
(Molecular Microbiology and Microbial Pathogenesis)
Washington University in St. Louis, 2017
Professor Daniel Goldberg, Chair
Human malaria is caused by five species of Plasmodium. Of these, P. falciparum is the deadliest
and is the only species that causes cerebral malaria (CM). CM is a disease of the vascular
endothelium characterized by parasite sequestration, increased inflammatory cytokine
production, vascular leakage and leukocyte infiltration. A distinguishing feature of P. falciparum
infection is the parasite’s production and secretion of histidine-rich protein II (HRPII). HRPII
accumulates to high concentrations (up to 100 µg/ml) in serum, which correlates with disease
severity. Due to high serum levels of this protein, HRPII has classically been considered a
biomarker for P. falciparum infection. Although many functions have been ascribed to HRPII,
the function of this protein remains ambiguous. Our work provides a new framework for
thinking of this protein from serum biomarker to parasite virulence factor. Using a cellular
model of the blood-brain barrier, we demonstrate that HRPII activates the innate immune system
in human cerebral microvascular endothelial cells, resulting in redistribution of tight junction
proteins and compromise of barrier integrity. This process is Myd88-dependent, NFĸB-mediated
and requires inflammasome activation. Intravenous infusion of HRPII induced vascular leakage
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in the cerebellum and cortex of mice and increased early mortality in a P. berghei ANKA
experimental cerebral malaria model. Analogously, transgenic P. berghei expressing falciparum
HRPII produced more severe disease than wild-type or control P. berghei. HRPII induced
endothelial expression of adhesion receptors used by plasmodium parasites, suggesting that this
protein also contributes to pathogenesis by enhancing parasite cytoadherence and thereby
avoiding splenic destruction. This study establishes that HRPII is a Plasmodium falciparum
virulence factor that triggers an innate immune inflammatory response in vascular endothelium
and contributes to cerebral malaria by compromising the integrity of the blood-brain barrier.
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Preface
The work presented in this thesis is one of several projects I have worked on during graduate
school; while this work progressed towards publication, most other projects did not. My favorite
of the failed projects was aimed at understanding how the parasite has adapted to living in such a
highly oxidative environment, and how it handles reactive oxygen species. Although the parasite
produces some proteins to handle oxidative stress, I wondered whether the parasite recruited
proteins from the host to complement the parasite arsenal. To try to understand this we initiated a
large scale immune-precipitation approach with various host proteins to identify parasite proteins
that may interact with them. Homologous parasite proteins complicated this approach so we next
went to a stem cell approach where we would tag host proteins in the red blood cell (prior to
differentiations, since RBCs eject their nucleus during development, this would not be possible
with more conventional approaches). While we were able to successfully differentiate RBCs
from human cord blood and modify with retroviruses, this was not a very large scale-able
approach and therefore not applicable for immuno-precipitation and mass spectrometry.

The project presented here focusing on HRPII also developed along a rather circuitous
path. Initial interest in HRPII was focused on its highly charged nature and its ability to bind to a
variety of glycosaminoglycans (GAGs). Glycosaminoglycans are present along all endothelial
cell surfaces and provide many functions including low affinity interactions between endothelial
cells and chemokines/ cytokines until they can bind to their receptors. This interaction mediates
directed migration of immune cells to areas of infection or damage. The rationale being if HRPII
could disrupt effective GAG: chemokine interaction, it could slow down the formation of an

xi

effective immune response. A delayed effective immune response to the parasite is characteristic
of patients displaying severe symptoms. Immunofluorescence assays revealed endothelial cells
whose cell membrane looked unhealthy in the presence of HRPII, and thereby a side
investigation became a new front focus. This new focus turned into a thesis project, and will be
the main work presented herein

xii

Chapter 1: Introduction
This chapter includes general background on malaria, the parasite and immunology that applies
to all sections; more relevant background will be present in separate chapters as needed.

1.1 Epidemiology and Pathophysiology
Malaria is a mosquito transmitted parasite illness present in some of the most economically
disadvantaged populations world-wide. According to recent WHO estimates roughly 3.3 billion
people are at risk for infection. This results in roughly 600,000 deaths, 90% of which are in
Africa- of these the majority are children under the age of five (World Health Organization,
World Malria Report, 2014)(Bell et al., 2006). Disappointingly, this infection is both preventable
and treatable. Although there has been a significant decline in transmission since 2000 due to
insecticidal sprays, insecticide treated bed nets, rapid diagnostic tests as well as increased access
to therapy and preventative therapy to pregnant women, there is also significant amount of work
remaining with the increasing challenge of parasites resistant to current drugs and mosquitos
resistant to insecticides.
Malaria in humans is caused by five parasite species, Plasmodium falciparum, Plasmodium
vivax, Plasmodium ovale, Plasmodium malariae and Plasmodium knowlsei.(Bell et al., 2006)
This obligate intracellular parasite is transmitted by the bite of an anopheles sp. mosquito; a
single successfully transmitted sporozoite can result in roughly 10,000 blood stage parasites, see
schematic of parasite life cycle in Figure 1 below borrowed from a review (Lycett and Kafatos,
[1]

2002).

Figure 1.1] Parasite life cycle borrowed from (Lycett and Kafatos, 2002)
Progression of the parasite out of the liver stage, initiates the blood stage of infection which is
associated with a majority of symptoms. The early symptoms are nonspecific and incudes
“headache, lassitude, fatigue, abdominal discomfort, and muscle and joint aches, usually
followed by fever, chills, perspiration, anorexia, vomiting and worsening malaise” (Reyburn,
2010). Treatment of a patient at this stage results in full rapid recovery, thereby underscoring the
importance of early detection and timely intervention. Treatment at a later stage, once organ
dysfunction has ensued and parasite burden has increased, often results in rapid progression to
severe malaria, particularly in the setting of a P. falciparum infection resulting in “coma
(cerebral malaria), metabolic acidosis, severe anaemia, hypoglycaemia, acute renal failure or

[2]

acute pulmonary oedema” (Reyburn, 2010). Severe malaria is almost always fatal when left
untreated, and about 20% fatal even with treatment.(Reyburn, 2010)
Cerebral Malaria
Cerebral malaria is the most severe manifestation of malaria infection and results in roughly
300,000 deaths annually. About 25% of survivors have lasting neurological complications
(Christensen and Eslick, 2015; Fernando et al., 2010). In a group of Ugandan children the
sequelae of cerebral malaria included spastic motor weakness, loss of speech, hearing deficits,
behavioral problems, epilepsy, blindness, and severe cognitive impairment (Idro et al., 2010).
Extensive neurological damage has been evidenced in pathology from patients who died from
cerebral malaria. Demyelination, damaged neurons, (Schluesener et al., 1998; Toro and Roman,
1978) parasitized capillaries, petechial hemorrhages are among the many changes observed on
autopsy specimens along with malarial retinopathy (hemorrhages, whitening and vascular
changes) (Taylor et al., 2004). Due to the variability and complexity of disease presentation,
pathologists have defined three predominant form of cerebral malaria defined by pathology
“CM1—clinical cerebral malaria with sequestration of parasitized red blood cells (PRBCs) in the
brain, no additional cerebral histopathological changes, and no other cause of death
CM2—clinical cerebral malaria with sequestration of PRBCs in the brain and the presence of
cerebral microthrombi, ring hemorrhages and extra-erythrocytic malaria pigment, and no other
cause of death

[3]

CM3—fulfilling the traditional definition of clinical cerebral malaria in life, but with no
sequestration of PRBCs in the brain and another cause of death identified” (Dorovini-Zis et al.,
2011; Milner et al., 2014; Taylor et al., 2004)
There are many models rationalizing the complex pathology present in cerebral malaria; the two
prevailing hypotheses are 1.) sequestration/ mechanical and 2.) immunopathology. The
mechanical notion suggests that multifocal lesions result from reduced blood flow from
sequestered parasites. This then causes metabolic changes: acidosis, hypoglycemia, and
hypoxemia which may conclude in a coma. However, this alone cannot account for the
pathology since similar levels of sequestration have been seen in patients not suffering from
cerebral malaria. The other dominant view suggests that an overactive immune response to the
parasite results in endothelial damage and dysfunction which eventually results in a breakdown
of the blood brain barrier and damage to the central nervous system as a byproduct of the
immune system attempting to clear the parasite. Cerebral malaria is a complex pathological
process and most likely results from a culmination of many factors.

1.2 Mouse Models for Cerebral Malaria
Plasmodium berghei ANKA infection of C57BL/6 mice is the most widely used murine model
for cerebral malaria infection (mCM). This model replicates many of the clinical and
histopathological features present in patients with human cerebral malaria (hCM). For example,
mCM displays tissue edema, hemorrhages, presence of an inflammatory infiltrate, activation of
microglia and a robust pro-inflammatory cytokine response. However, there are limited infected
[4]

red blood cells sequestered along the vascular endothelium and an a more robust inflammatory
infiltrate than that present with hCM.
A very extensive debate on the validity of the model has been ensuing through articles and at
conferences (Hunt et al., 2010; Renia et al., 2010; Riley et al., 2010; Stevenson et al., 2010;
White et al., 2010). Amongst the most compelling arguments against using the murine cerebral
malaria model is that 44 out of 48 therapies assessed in mCM model were successful in healing
mice; however, of 17 assessed in human, only one has shown some efficacy. This underscores
that the biology in these two distally related mammals may not be close enough to develop
effective therapeutics. The main features differentiating murine cerebral malaria and hCM are
highlighted below in a table borrowed from a recent review. (Medana et al., 2001)

Table 1] Major differences between human cerebral malaria and the murine model, P.
berghei ANKA
Despite the controversy present around the berghei mouse model, there is some advantage to
studies that use it. At a first pass, it is important to remember that the berghei model is at the end
of the day a model and therefore an approximation of what happens in the human cerebral
malaria case and not a replicate. It provides a glance to how different factors will affect the
infection in the presence of an immune system, other organs, a vasculature, and many other
components. It is of particular ease of use when studying factors exclusive to P. falciparum and
[5]

not present in P. berghei. In this setting, the berghei model provides a background akin to a
knock-out. As a consequence it is simple to compare infection in an isogenic background with
one protein different. The studies we have performed using P. berghei ANKA added a protein
present only in P. falciparum, HRPII. We were able to demonstrate that addition of HRPII into
the berghei genome reduced mouse survival and was therefore important for the parasite outside
of simple parasite growth as we suspected.

1.3 HRPII
Histidine rich protein II (HRPII) is a protein produced exclusively by Plasmodium falciparum
and exported out of the parasitophorous vacuole into the red blood cell. Upon RBC lysis HRPII
is released into the blood stream where it is found at concentrations > 1000ng/mL (Dondorp et
al., 2005) and can be detected at least 1 month post clearance of parasites. HRPII is a curious
protein not only due to its biochemical properties, but because it is only present in the P.
falciparum genome. HRPII is highly basic, composed 37% by histidines; two repeats (His- HisAla-His-His-Ala-Ala-Asp-Ala and His-His-Ala-Ala-Asp) cover 85% of its sequence. The
sequence shown below highlights the histidine rich nature of the sequence. Since its discovery in
1986 (Wellems and Howard, 1986), many functions have been ascribed to it including hemozoin
crystallization, actin formation, T cell suppression, glycosaminoglycan binding and
procoagulation (Benedetti et al., 2003; Choi et al., 1999; Das et al., 2006; Mashima et al., 2002;
Ndonwi et al., 2011; Sullivan et al., 1996). It has been shown to interact selectively with
heparin, heparan sulfate and dermatan sulfate with high affinity (Ndonwi et al., 2011). This
particular interaction led to the discovery of its procoagulant property, and may explain the procoagulant state seen during P. falciparum infection. Heparin at low concentrations is known to
[6]

bind to the serpin antithrombin III and increase heparin’s inhibition of Factor Xa or thrombin
2000-4000 fold. HRPII has been shown by our lab to neutralize this enhancement of
antithrombin activity and thereby promote a pro-coagulative environment. (Ndonwi et al., 2011)

Figure 1.2] Amino Acid sequence of HRPII from P. falciparum
HRPII is produced by almost all natural isolates of Plasmodium falciparum. Due to its presence
at high concentrations in infected individuals it has been used as a biomarker for infected
individuals and forms the basis of the dipstick test (Chiodini et al., 2007; Dondorp et al., 2005;
Moody, 2002; Parra et al., 1991). The asexual stages of infection by all other species occur
exclusively in the blood stream and therefore blood parasitemia is a decent indicator of parasite
burden. In contrast, P falciparum parasites in the trophozoite and schizont stages are sequestered
[7]

along endothelial walls and can rarely be seen in the blood stream; therefore blood parasitemia is
a poor indicator of parasite burden. Since HRPII is released into the blood stream as schizonts
rupture, and is cleared from the blood stream slowly; HRPII serves as a good measure of recent
P. falciparum infection.
HRPII has been used as a biomarker for P. falciparum infection and forms the basis of current
rapid diagnostic tests (Chiodini et al., 2007; Dondorp et al., 2005; Moody, 2002; Parra et al.,
1991). On post-mortem analyses, HRPII has been observed to line the endothelial walls of blood
vessels (Aikawa et al., 1990). Several correlative studies have shown an association between
HRPII levels in acute serum and disease severity or development of CM (Dondorp et al., 2005;
Fox et al., 2013; Hendriksen et al., 2012; Hendriksen et al., 2013; Kariuki et al., 2014; Seydel et
al., 2012). Natural populations of HRPII-deficient Plasmodium falciparum parasites exist
(Gamboa et al., 2010; Koita et al., 2012; Kumar et al., 2013), though these tend to be in areas of
low CM incidence. We questioned whether HRPII might contribute to disease pathogenesis

1.4 Blood Brain Barrier and Vascular endothelium
The BBB regulates access of peripheral circulatory compounds and cells to the central nervous
system. The BBB is formed by a complex network of intercellular junctional proteins. It is
supported by many components a basement membranes, a complex extracellular matrix and
various cells including astrocytes and microglia (Kawai and Akira, 2010). “Astrocytes, pericytes
and extracellular matrix (ECM) components provide both structural and functional support to the
BBB. The term ‘neurovascular unit’ (NVU) additionally refers to neurons, microglial cells and,
optionally, peripheral immune cells that also contribute to this cellular interplay” (Obermeier et
al., 2013). A schematic from a recent review is shown below Disruption of this network results
[8]

in BBB compromise and has been linked to a various disease states.

Fig 1.3 ] Neurovascular unit of the blood brain barrier. Figure borrowed from (Obermeier
et al., 2013)

The endothelial cells that line the vasculature in the brain are distinct from those in other organs
in part due to the stringency and selectivity guiding which compounds can permeate past this
endothelial lining. This selective barrier between the peripheral circulatory components of the
blood and the brain, the blood brain barrier proper “lies in the presence of tight junctions
between the cerebral endothelial cells of the vasculature of the brain both within the parenchyma

[9]

and over the surface in the pia-arachnoid” (Stolp et al., 2013). Tight junctions prevent the
paracellular transport of molecules into the parenchyma of the brain.
We used an in vitro model blood brain barrier to study how different components affect it. An
illustration is shown below in figure 1.4. We culture a human brain cerebrovascular
immortalized endothelial cell line hCMEC/D3 cells on collagen coated trasnwell inserts. The
cells are allowed to grow to complete confluence and during this time they form appropriate tight
junctions as previously described (Daniels et al., 2013; Weksler et al., 2005). We can measure
the electrical resistance across this endothelial monolayer, high resistance values are indicative
of an intact barrier while decreasing resistance values indicate a compromised model blood brain
barrier.

Figure 1.4] Model BBB
[10]

1.5 Inflammasome
The innate and adaptive immune system work together to alert the host of danger signals both
foreign and inappropriate host responses. The innate system is activated first and responds to a
wide range of pathogenic or host patterns that have evolutionarily been deemed dangerous, and
activates the adaptive immune response which is able to mount a specific response via B and T
cells. (Basset et al., 2003). The innate immune system operates through PRRs (pathogen
recognition receptors) which recognize PAMPs (pathogen associated molecular patterns). The
innate immune system can also be activated by components released by injured cells termed
danger associated molecular patterns (DAMPs) such as mammalian double stranded DNA and
uric acid crystals (Ishii et al., 2001; Martinon et al., 2006). So the innate immune system
recognizes common patterns from invading bacteria viruses and fungi as well as damage
resulting from the invasion to the host. PRRs can be cytoplasmic, membrane bound or even
secreted and are present in specialized immune cells such as macrophages, monocytes, dendritic
cells (DCs), neutrophils, in addition to normal mononuclear endothelial and epithelial cells. Tolllike receptors (TLRs) are one set of well-established PRRs (O'Neill and Bowie, 2007). More
recently discovered PRRs are RIG-like helicases (RLH) and NOD- like receptors (NLRs) which
are soluble cytoplasmic receptors unlike TLRs which are membrane bound (Martinon and
Tschopp, 2005; Yoneyama et al., 2004). NLRs are a common class of sensor molecules for
inflammasomes.
Inflammasomes are large molecular weight complexes that recognize pathogenic or sterile
danger molecules and activate the pro inflammatory cytokines IL-1β (interleukin 1 beta) and IL18 (interleukin 18) (Latz et al., 2013). The complex is formed from the association of a sensor
[11]

molecule, the adaptor protein ASC which recruits caspase-1 and caspase-1. The adaptor protein
ASC has two death- fold domains: a pyrin domain and a caspase activation and recruitment
domain (CARD) (Vajjhala et al., 2012). The pyrin domain allows for association with the
upstream sensor molecule and the CARD domain brings pro caspase-1 molecules in close
proximity allowing cleavage and self-activation. Active caspase-1 molecules are able to cleave
pro- IL-1β and pro IL-18 into their respective active forms IL- 1β and IL-18. Many sensor
molecules have been identified such as NLRP1, NLRP3, NLRP12, NAIP1, NAIP2, NAIP5, or
AIM2 and are collectively able to detect a diverse array of host and pathogenic danger signals.
Activation of the inflammasome eventually results in a form of programmed inflammatory cell
death known as pyroptosis. Although activation of the inflammasome is often thought of in the
context of a bacterial infection or host danger molecules, it can also be activated from an
intracellular protozoan parasite infection (Zamboni and Lima-Junior, 2015).

[12]

Fig 1.5 Inflammsome highlighting the many points of activation borrowed from (Latz et al.,
2013)
The work that follows was pursued to understand the function of HRPII, a parasite protein that is
biochemically very unique, produced at high levels and whose serum levels correlate with
disease severity and cerebral malaria. We reasoned that a function should exist since the protein
is produced to such high levels. In addition, early work had shown that parasites were viable in
the presence of a genetic deletion of HRPII, in fact, natural HRPII null parasites exist. Therefore,
we hypothesized that a function for HRPII, if existed, would be not be in parasite growth, but
perhaps something important during the life cycle in the host. In consideration of the correlation
between HRPII levels and cerebral malaria, we began studying HRPII on human brain
[13]

endothelial cells. Interesting findings led to the work described in chapter 2.

[14]
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Chapter 2: A role for HRPII in cerebral
malaria pathogenesis
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2.1 Abstract
Human malaria is caused by five species of Plasmodium. Of these, P. falciparum is the deadliest
and is the only species that causes cerebral malaria (CM). CM is a disease of the vascular
endothelium characterized by parasite sequestration, increased inflammatory cytokine
production, vascular leakage and leukocyte infiltration. A distinguishing feature of P. falciparum
infection is the parasite’s production and secretion of histidine-rich protein II (HRPII). HRPII
accumulates to high concentrations (up to 100

g/ml) in serum, which correlates with disease

severity. Using a cellular model of the blood-brain barrier, we demonstrate that HRPII activates
the innate immune system in human cerebral microvascular endothelial cells, resulting in
redistribution of tight junction proteins and compromise of barrier integrity. This process is
Myd88-dependent, NF B-mediated and requires inflammasome activation. Intravenous infusion
of HRPII induced vascular leakage in the cerebellum and cortex of mice and increased early
mortality in a P. berghei ANKA experimental cerebral malaria model. Analogously, transgenic P.
berghei expressing falciparum HRPII produced more severe disease than wild-type or control P.
berghei. HRPII induced endothelial expression of adhesion receptors used by plasmodium
parasites, suggesting that this protein also contributes to pathogenesis by enhancing parasite
cytoadherence and thereby avoiding splenic destruction. This study establishes that HRPII is a
Plasmodium falciparum virulence factor that triggers an innate immune inflammatory response
in vascular endothelium and contributes to cerebral malaria by compromising the integrity of the
blood-brain barrier.
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2.2 Introduction
Malaria infections cause an estimated 627,000 deaths per year, with 90% occurring in
Sub-Saharan Africa, primarily in children under five (WHO World Malaria Report 2013). Of the
five species of Plasmodium capable of infecting humans, P. falciparum causes the most
morbidity and mortality (MacPherson et al., 1985). The clinical presentation of malaria ranges
from a simple febrile illness (uncomplicated malaria) to various syndromes alone or in
combination, including severe anemia, respiratory distress multi-organ failure, and cerebral
malaria (CM) (Miller et al., 2002). CM is a deadly manifestation that is caused almost
exclusively by P. falciparum. Patients present with decreased sensorium progressing to coma.
This neurological syndrome is characterized by sequestration of infected RBCs in
cerebrovascular beds, vascular occlusion, leukocyte infiltration, pro-inflammatory cytokines,
perivascular edema, brain swelling and a diffuse encephalopathy (Engwerda et al., 2005;
Menezes et al., 2012; Pongponratn et al., 2003; Seydel et al., 2015). CM results in about 300,000
deaths annually, has a 20-30% case fatality rate despite treatment (Brewster et al., 1990; Idro et
al., 2005), and 25% of survivors have lasting neurological sequelae (Fernando et al., 2010),
including cognitive impairment (Idro et al., 2010). Infection of mice with the rodent malaria
parasite strain P. berghei ANKA serves as a model for cerebral malaria. The pathology present in
experimental cerebral malaria (eCM) is similar to that in human cerebral malaria (CM) with
notable exceptions of limited sequestration of infected RBCs, a more robust infiltration of
leukocytes and a different quality of the immune response (Medana et al., 2001; White et al.,
2010). The biological basis of these differences is poorly defined but the topic of spirited debate
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and an active area of research (Craig et al., 2012; de Souza et al., 2010; de Souza and Riley,
2002; Riley et al., 2010).
Histidine-rich protein II (HRPII) is a unique protein produced exclusively by P.
falciparum. It is highly basic: 37% of its amino acid sequence is histidine and repeats of histidine
plus alanine cover 85% of its sequence. HRPII is exported by the parasite into the RBC cytosol
(Howard et al., 1986). Upon maturation of the parasite and rupture out of the host cell, the
contents of the RBC cytosol including HRPII are released into the bloodstream (Parra et al.,
1991). In serum, it can be detected at high concentrations (~1-100

g/mL) and can be detected at

least 1 month post clearance of parasites (Dondorp et al., 2005). Since its discovery in 1986
(Wellems and Howard, 1986), many functions have been ascribed to it including hemozoin
crystallization, actin formation, T cell suppression, glycosaminoglycan binding and
procoagulation (Benedetti et al., 2003; Choi et al., 1999; Das et al., 2006; Mashima et al., 2002;
Ndonwi et al., 2011; Sullivan et al., 1996).
HRPII has been used as a biomarker for P. falciparum infection and forms the basis of
current rapid diagnostic tests (Chiodini et al., 2007; Dondorp et al., 2005; Moody, 2002; Parra et
al., 1991). On post-mortem analyses, HRPII has been observed to line the endothelial walls of
blood vessels. Several correlative studies have shown an association between HRPII levels in
acute serum and disease severity or development of CM (Dondorp et al., 2005; Fox et al., 2013;
Hendriksen et al., 2012; Hendriksen et al., 2013; Seydel et al., 2012). Natural populations of
HRPII-deficient Plasmodium falciparum parasites exist (Gamboa et al., 2010; Koita et al., 2012;
Kumar et al., 2013), though these tend to be in areas of low CM incidence.
We questioned whether HRPII might contribute to disease pathogenesis. Herein, we
provide evidence that HRPII is a P. falciparum virulence factor that triggers the inflammasome
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in vascular endothelial cells. HRPII binding to brain endothelial cells results in rearrangement of
tight junction proteins and a compromised blood-brain barrier (BBB). We propose that HRPII
contributes to the pathogenesis of cerebral malaria.

2.3 Results
HRPII is both necessary and sufficient to compromise endothelial barrier integrity
Prior work has shown that addition of cultured P. falciparum parasites to brain endothelial cells
compromises barrier integrity (Tripathi et al., 2007), and that soluble factors released during
infection are adequate to mediate this phenotype. Due to the established correlation between
HRPII and disease severity (Dondorp et al., 2005; Fox et al., 2013) we assessed the consequence
of HRPII exposure using an in vitro BBB model of human cerebral microvascular endothelial
cells (hCMEC/D3) grown on trans-well porous inserts (Daniels et al., 2013) The upper chamber
of this cellular model represents the luminal face of a blood vessel; P. falciparum clone 3D7
parasitized erythrocytes were added to the upper chamber and trans-endothelial electrical
resistance (TEER) was measured across the endothelial barrier. These parasites induced a timedependent decrease in resistance (Fig 2.1A). In contrast, clone Dd2, which contains a deletion of
the HRPII gene, caused minimal change in barrier integrity. Wild-type Dd2 parasites were
transfected to generate transgenic parasites that ectopically express HRPII. Integration of the
gene for HRPII was confirmed by PCR and isolated clones demonstrated an ability to produce
HRPII by western blot (Fig 2.2). Two clones expressing HRPII from independent transfections
compromised barrier integrity (Fig 2.1B).
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Figure2.1] HRPII is both necessary and sufficient to compromise the integrity of an in vitro
BBB. Trans-endothelial electrical resistance (TEER) was measured across an hCMEC/d3
monolayer over time, and components for assessment were added to the upper chamber. (A)
Addition of 10^8 uninfected RBCs, Plasmodium falciparum strain Dd2 (which does not produce
HRPII) and strain 3D7 (which produces HRPII) were added to the BBB model. All values are
relative to resistance measurements at time 0. Data are mean values +/- SEM for 2 replicates.
Curves are significantly different from 3D7 chambers by one-way ANOVA. (B) Addition of
10^8 Dd2 parasites, parasites engineered to produce HRPII (Dd2/ gHRPII-1 and Dd2/gHRPII-2),
Dd2 parasites with 10 µg of added recombinant HRPII (Dd2/ rHRPII ), or in the presence of
specific antibody (Dd2/ gHRPII/ αHRPII). Data are mean values +/- SEM for 6 replicates spread
over 3 independent experiments. Difference from untreated *p < 0.0001 and ** p < 0.009 by
one-way ANOVA. (C) Addition of recombinant purified HRPII (rHRPII), HRPII purified from
3D7 parasites (native HRPII) or in combination with monoclonal anti- HRPII antibody (αHRPII)
or isotype control (Iso). Data are mean values +/- SEM from a 24 hour time point for 4-8
replicates spread over 5 independent experiments. Difference from untreated p < 0.0001, by oneway ANOVA.
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Figure 2.2] Dd2 transgenic parasites clones have been successfully transfected with the
gene encoding HRPII-GFP and produce protein. (A) PCR of the HRPII gene from wild-type
Dd2 (lane1,4) parasites as well as the transgenic clones C5 (lanes 2,5) and D3 (lanes 3, 6)
amplifying for HRPII (lanes 1-3) and HRPII-GFP (lanes 4-6). (B) Western blots of parasite
extracts from wild-type Dd2 (lane1), 3D7 (lane 2), clone C5 (lane 3), clone D3 (lane 4). WB
using anti-HRPII (clone 2G12, 1:10,000). The yellow box highlights the band for HRPII-GFP,
and the white box highlights native untagged HRPII. Both transgenic clones gave similar results
in the TEER assay.
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Addition of a neutralizing anti-HRPII monoclonal antibody to the upper chamber confirmed the
specific effect of HRPII as it abolished the barrier compromise observed using the transfected
parasites. Addition of recombinant HRPII to wells containing wild-type Dd2 parasites also
resulted in barrier compromise. These experiments demonstrate that HRPII is required for
parasites to disrupt endothelial barrier integrity. Subsequent studies revealed that purified HRPII
alone (recombinant or isolated from P. falciparum 3D7 parasites) similarly disturbed barrier
integrity (Fig 2.1C). This activity was specific, as antibody blockade of HRPII abolished the
effect. These experiments establish that HRPII is both necessary and sufficient to compromise
endothelial barrier integrity.
HRPII results in redistribution of tight junction and adherens junction proteins.
The BBB regulates access of peripheral circulatory compounds and cells to the central
nervous system. The BBB is formed by a complex network of intercellular junctional proteins,
basement membranes, and various cells including astrocytes and endothelial cells (Kawai and
Akira, 2010). Disruption of this network results in BBB compromise and has been linked to a
various disease states.
We queried whether HRPII caused altered localization of junctional proteins contributing
to compromised barrier integrity. Immunohistochemical detection within hCMEC/d3 cells for
several junctional proteins and their intracellular adaptors, revealed redistribution of the tight
junction protein claudin-5 (Cld-5) and the adherens junction protein VE-cadherin (Fig 2.3A).
Zona-occludens-1 (ZO-1), the intracellular adaptor for claudin-5, stained poorly in the
hCMEC/D3 cell line. Therefore, we stained for ZO-1 on Caco-2 cells and observed clear
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alteration of its distribution from cell borders to a diffuse cytoplasmic staining in the presence of
HRPII (Fig 2.3B), similar to what was observed with LPS.

Figure 2.3] HRPII exposure to human cerebral microvascular endothelial cells results in
redistribution of junctional proteins. (A) hCMEC/d3 monolayer cultures were incubated 24
hours with 25 µg of BSA or HRPII, or 3 µg of LPS, staining for tight junction protein claudin-5
and the adherens junction protein VE-cadherin. (B) Caco-2 cultures were treated as in (A) and
stained for Zona occludens-1 (ZO-1), the intracellular adaptor for claudin-5 and nuclei (DAPI).
Representative images of 4 replicates from 2 independent experiments. All images taken using
the same settings. Arrows highlight areas of incomplete staining.

HRPII activates an innate immune responses in endothelial cells
The disruption of BBB integrity by HRPII indicated that endothelial cells respond to the
protein. We next questioned whether this was an immunological response. Quantitative RT-PCR
analysis of chemokine and cytokine transcripts in hCMEC/D3 cells showed that several were up38

regulated within 8 hours post exposure to recombinant HRPII (Fig 2.4A), and the response was
kinetically different from that observed with LPS (Fig 2.5). As transcription of chemokines and
cytokines can be induced by NFĸB activation (Lawrence, 2009), we tested whether the HRPII
effects were mediated via NFĸB signaling.

Figure 2.4] HRPII activates an inflammatory pathway in human cerebral microvascular
endothelial cells. (A) qRT-PCR of chemokine/ cytokine mRNA levels of hCMEC/d3 cells
treated with 25 µg HRPII or BSA for 8 hours. *p = 0.0079, by two tailed t- test. (B) TEER
measurements for in vitro BBB barriers transfected with shRNAs for NFĸB (N1 and N3) or a
scrambled control (Sc) for 36 hours or incubated with inhibitors for NFĸB, Celastrol (Ce) and
Triplotide (Tr) for 2 hours prior to addition of HRPII (H, 10 ug). Data are mean values +/- SEM
for 6-8 replicates spread over 3 independent experiments. All curves are significantly different
from scrambled, HRPII-treated control chambers p < 0.0001, by one-way ANOVA. (C) TEER
measurements for in vitro barriers transfected with shRNAs to MyD88 (M1, M3 and M5) or a
scrambled control (Sc) for 36 hours prior to addition of recombinant purified HRPII (10 µg).
Data are mean +/- SEM from 6-8 replicates over 3 independent experiments. All treatment
groups are different from scrambled, HRPII-treated control chambers p<0.0001, by one-way
ANOVA. Assessment of knockdown levels shown in figure 2.6. (D) TEER measurements for in
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vitro BBB barriers transfected with shRNAs for caspase 1 (C1 and C2) or a scrambled control
(Sc) for 36 hours or with IL1Ra (500 ng), αIL-1β (25 ng) or the caspase-1 inhibitor YVAD-CMK
(80 µM) (C1 Inh) for one hour prior to treatment with recombinant purified HRPII (10 µg, H).
Data are mean values +/- SEM for 6-8 replicates spread over 4 independent experiments. All bars
are significantly different from HRPII treated, p < 0.05 by one-way ANOVA.

Two different chemical inhibitors of NFĸB (targeting subunit p65), Triplotide (Zeng et al., 2011;
Zhu et al., 2009) and Celastrol (Ni et al., 2014; Yang et al., 2006), ablated the TEER changes
induced by recombinant HRPII and resulted in normalized barrier integrity (Fig 2.4B). To
confirm independently the role of NFĸB in HRPII-mediated effects on barrier integrity, we
silenced the p105 subunit of NFкB (Fig 2.6). Again, a decrease in TEER was prevented (Fig
2.4B). These experiments suggest that the HRPII-mediated drop in TEER requires an NFĸBdependent signal.

Figure 2.5] HRPII and LPS induce chemokines and cytokines with distinct kinetic profiles.
Up-regulation of chemokine and cytokine mRNA levels seen in response to 25 µg HRPII or LPS
at 8, and 24 hours post exposure. Fold mRNA induction relative to untreated cells.
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Many cellular pathways can activate NFĸB signaling. To begin to define the HRPIIdependent pathway we silenced the most common intracellular adaptor, MyD88 (Fig 2.6).
Knocking down MyD88, significantly reduced the drop in TEER present from HRPII by three
different shRNAs (Fig 2.4C). These data highlight that HRPII-mediated inflammation is NFĸB
and MyD88- dependent.

Figure 2.6] Knockdown levels of the various shRNAs used. shRNAs to TLR2 (2-1 and 2-2),
TLR5 ( 5-3, 5-4), TLR9 (9-3, 9-4), NFkB (N1 and N3), to Myd88 (M1, M3 and M5), to caspase
1 (C1 and C2). hCMEC/D3 cells were incubated with shRNAs as in Figure 3. mRNA levels were
quantified by qRTPCR. Shown are data from triplicate determinations. Values are normalized for
percent of cells transfected, as determined from visualization of GFP-expressing shRNA.

HRPII activates the inflammasome
MyD88 is an intracellular adaptor for a number of innate immune receptors, and several
of these proteins use MyD88 as an exclusive intracellular adaptor: TLR1/2, TLR2/6, TLR5,
TLR7, TLR9, IL-1R and IL-18R (Kawai and Akira, 2005, 2010). Silencing of TLR2, 5, and 9
(Fig 2.6) did not impact HRPII-mediated endothelial cell barrier disruption (Fig 2.7).
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Figure 2.7] HRPII-mediated BBB compromise does not require TLR 2, 5 or 9. TEER
measurements for in vitro BBB models transfected with scrambled control (Scrb) or shRNAs to
TLR2 (2-1, 2-2), TLR5 (5-3, 5-4), and TLR9 (9-3, 9-4).

However, using a neutralizing polyclonal antibody against IL-1β or using IL1Ra, a natural
antagonist of IL-1R, we demonstrated that HRPII-mediated change in TEER requires IL-1β
activation and signaling (Fig 2.4D). These data point to involvement of the inflammasome. A
requirement for caspase-1 was confirmed using two distinct shRNAs for caspase-1 as well as the
caspase-1 specific inhibitor YVAD-CMK. Endothelial barriers treated with these reagents did
not display a change in TEER in the presence of HRPII (Fig 2.4D). These data indicate that
activation of the inflammasome is required for HRPII-mediated BBB disruption.
HRPII-induced cell death and loss of barrier integrity are independent and kinetically
distinct phenotypes
Activation of the inflammasome can cause cell death. To determine whether endothelial
cells lose viability in response to HRPII exposure, we monitored cell death at various time
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points. Cells undergoing programmed cell death display nicked DNA which can be visualized
with a TUNEL stain. HRPII-treated cells showed no TUNEL staining at 6 hours (when barrier
disruption is evident) although nicking of cellular DNA was evident at 24 hours post exposure
(Fig 2.8A).
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Figure 2.8] HRPII mediated BBB compromise is independent of cell death. (A) HRPII
results in cell death, evidenced by nicked DNA in this TUNEL stain at 24 hours post exposure to
protein, but not at 6 hours. Cyclohexamide (CHX) is a positive control for cell death (B) TEER
measurements for in vitro BBB models untreated, treated with IFN-y (10 ng), or HRPII, or
cyclohexamide (CHX, 10 ng/mL) in the absence (blue) or presence (red) of an apoptosis
inhibitor (Z-VAD-FMK, 10 µg/mL).

To rule out the possibility that HRPII-mediated loss of barrier integrity was a consequence of
cell death, we reassessed TEER changes in the presence of an apoptosis inhibitor, Z-VAD-FMK.
In this experiment, cycloheximide (CHX) serves as a positive control for endothelial cell
disruption via apoptosis. In the presence of the Z-VAD-FMK, cell death and barrier leakage by
CHX was prevented. IFN-γ serves as a second control for TEER changes via a mechanism
(rearrangement of junctional proteins) that is distinct from cell death. IFN-γ compromised barrier
integrity even in the presence of the apoptosis inhibitor. Similar to the IFN-γ control, HRPIImediated TEER changes were sustained when cells were treated with Z-VAD-FMK (Fig 2.8B).
These data indicate that the loss of barrier integrity induced by HRPII is not a byproduct of cell
death.
HRPII promotes BBB permeability in vivo
To determine whether the HRPII could induce a compromise in barrier integrity of brain
endothelial cell monolayers in vivo, four week-old female C57BL/6 mice were administered two
200 µg doses of HRPII 24 hours apart by intravenous injection. Forty-eight hours after the first
dose, mice were injected via an intraperitoneal route with sodium fluorescein. 45 minutes later,
animals were perfused and levels of fluorescein were measured in the brain parenchyma. We
observed an increase in vascular leakage of fluorescein into the cortex and cerebellum of mice
infused with HRPII compared to control animals (Fig 2.9A, B). Peak serum HRPII levels at 1
hour post infusion were found to be around 300-400 ng/mL. At the time of harvest, HRPII levels
44

were 150-200 ng/mL, substantially lower than levels observed in patients with cerebral malaria,
where 1 to 100 µg/mL has been reported (Dondorp et al., 2005). Presumably much of the HRPII
redistributes to the vascular wall, where it can be seen lining the endothelial surface in mice (Fig
2.9C) as it is in humans.

Figure 2.9] HRPII causes IL-1β mediated vascular leakage in vivo. HRPII (200 µg) was
injected into 4 week old female mice. After 48 hours, fluorescein was injected and levels
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measured in the cortex (A) and cerebellum (B). HRPII treatment was significantly different from
control. Fluorescein levels in the cortex (A) and cerebellum (B) of mice infused with HRPII
along with an iso-type antibody control (Iso), or a αIL-1β antibody, compared to just αIL-1β
treated or untreated mice. HRPII-iso is significantly different from HRPII/ αIL-1β, p= 0.004
(cerebellum) and p= 0.06 (cortex), by one way ANOVA. (C) 4 week old female mice infused
with 50ug HRPII. Representative immunohistochemistry sections showing persistent vascular
staining with HRPII over five days. (D) 4 week old female mice infused once with 50 µg of BSA
or HRPII prior to infection with P. berghei ANKA (10^5 parasites). Data are mean +/- SEM for
24-27 mice over 4 independent experiments. Curves are sig different, p = 0.03, by Log-Rank
(Mantel-Cox test) (E) 4 week old female mice infected with P. berghei ANKA wild-type
parasites or a transgenic line created to express HRPII (10^5 parasites). Data are mean +/- SEM
for 35-41 mice over 4 independent experiments. Curves are sig different, p < 0.0001, by LogRank (Mantel-Cox test).

Our in vitro BBB model indicated that HRPII-mediated permeability was inflammasome
dependent. To assess this effect in vivo, we infused HRPII-treated mice with a neutralizing
antibody to IL-1β or an isotype control (Fig 2.9A, B). IL-1β specific antibody blocked HRPIIinduced sodium fluorescein leakage. These data confirm the in vivo relevance of IL-1β-mediated
signaling for the actions of HRPII on BBB permeability.
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HRPII reduces survival in an experimental cerebral malaria model

Figure 2.10] Parasitemia of mice dying from cerebral malaria-like symptoms is low, and
the parasitemia of mice infused with HRPII or control protein is similar. Representative
parasitemia from one full experiment. Mice displaying cerebral malaria-like symptoms died at
low parasitemia by day 10, and parasitemia between both groups were closely matched on each
day. Representative data from one experiment, 10 mice per group. Experiment was repeated
three times.

We next determined whether the compromise in vascular integrity observed with purified HRPII
had functional consequences during a malaria infection. We infused 6 week old female
C57BL/6J mice with 50 µg of BSA or HRPII prior to infection with 2 x105 P. berghei ANKA.
The experimental cerebral malaria model has variable penetrance, with a 40 to 100% lethality
rate from cerebral malaria reported (de Oca et al., 2013; de Souza and Riley, 2002), defined as
neurological symptoms and death at or below 10% parasitemia, by day 10 post infection. Mice
infused with HRPII had a statistically significant increased incidence of neurological symptoms
and early lethality compared to control mice (Fig 2.9D). The parasitemia of mice that died from
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cerebral malaria-like symptoms was low, as expected (Fig 2.10), and importantly no differences
were observed between mice infused with HRPII or control protein.
As a further test of the role of HRPII in the cerebral malaria model, we generated
transgenic P. berghei ANKA parasites that express HRPII. Insertion of the gene was confirmed
by PCR, and sequence confirmed by TOPO-TA cloning and sequencing of the insert (Fig 2.11).
Expression of HRPII was confirmed by quantitative ELISA. Levels of HRPII in the serum of
mice at day 8 after infection were 100 to 200ng/mL (data not shown). Mice infected with
transgenic parasites also had a more rapid time to death compared to those infected with the
parental line (Fig 2.9E).

Figure 2.11] Transgenic P. berghei ANKA parasites carry the gene for HRPII (A) PCR of
HRPII from genomic DNA purified from whole blood of mice infected with wild -type P.
berghei ANKA parasites (lane 1) or those engineered to produce HRPII (lane 2) using primers at
the 5’ and 3‘ ends of the HRPII-GFP. (B) PCR to illustrate integration of HRPII from genomic
DNA purified from whole blood of mice infected with wild -type P. berghei ANKA parasites
(lane 1, 3) or those engineered to produce HRPII (lane 2, 4) using primers resting upstream of
the 5’ 230p integration site (forward) and the end of GFP (reverse), lanes 1 and 2. Lanes 3 and 4
use primers resting at the start of HRPII (forward) and post the 3’ integration site of 230p (rev).
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HRPII treatment upregulates cytoadherence molecules on endothelial cells
Cerebral malaria is accompanied by upregulation of cytoadherence molecules on the
vascular endothelium (Hawkes et al., 2013; Madkhali et al., 2014; Storm and Craig, 2014). We
assessed the surface expression of several relevant adhesion receptors on brain microvascular
endothelial cells after treatment with HRPII. The expression of ICAM-1 and VCAM-1 was
increased upon HRPII treatment (Fig 2.12). In contrast, E-selectin was not increased. ICAM-1
expression levels and binding by parasites is known to be associated with severity of disease
(Madkhali et al., 2014).

Figure 2.12] Human brain microvascular endothelial cells exposed to HRPII display an
increase in surface adhesion receptors. Human brain endothelial cells were exposed to BSA
or HRPII (10 µg) for 24 hours. Surface expression of cell surface adhesion receptor is measured
by flow cytometry. Using a two tailed t-test, p< 0.03 for ICAM-1 and VCAM-1 expression, E49

Selectin expression is not significantly different between BSA and HRPII treatment.
Representative flow plots shown below each bar graph.

2.4 Discussion
BBB leakage during Plasmodium falciparum infection is a hallmark of CM. The
pathophysiology underlying this effect, however, is poorly understood. Our study has identified
HRPII as a parasite virulence factor that is recognized by the host innate immune system,
activates the inflammasome and promotes redistribution of endothelial junctional proteins, which
results in increased BBB permeability.
P. falciparum parasites produce two highly homologous histidine-rich proteins: HRPII
and HRPIII. Of the two, HRPII is produced abundantly whereas HRPIII is minor (Rock et al.,
1987). These proteins are exported by the parasite into the host erythrocyte and then gain access
to the host bloodstream, largely after parasite rupture (Desakorn et al., 2005; Howard et al.,
1986; Rock et al., 1987). The Dd2 P. falciparum parasite strain produces only HRPIII and has a
deletion in HRPII. Using this background strain, we generated transgenic parasites that express
HRPII, and isolated two clones from independent transfections. Whereas parental Dd2 parasites
caused minimal change in TEER in an in vitro human BBB model, the HRPII-expressing clones
caused a substantial decrease in TEER, similar to that seen with the 3D7 P. falciparum isolate
that endogenously expresses HRPII. Evidently, the small amount of HRPIII expressed in Dd2 is
not sufficient to effect barrier disruption. HRPII, the major histidine-rich protein, appears to be
responsible for this action on the endothelium.
Several lines of experimental evidence suggest that a direct effect of HRPII is responsible
for BBB leakage: (1) P. falciparum strains that naturally carry the HRPII gene or have been
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genetically modified to carry it can compromise the integrity of an in vitro BBB model; (2)
purified native and recombinant HRPII can mediate decreased TEER directly; (3) a monoclonal
antibody to HRPII neutralizes both the infected RBC-mediated and the isolated protein-mediated
effects on TEER; (4) HRPII infusion at clinically relevant levels causes leakage of sodium
fluorescein into the brain parenchyma of mice. This last statement is complicated by the
pharmacokinetics of HRPII in mice and humans. While HRPII in humans can be detected
roughly one month post clearance of parasites, in mice the half-life is roughly 24 hours. Despite
this, vascular leakage was observed with infusion of HRPII that gave peak concentrations lower
than those in human cerebral malaria.
Assessment of transcriptional responses to HRPII suggested activation of the NF B
pathway. Gene silencing and antagonist experiments confirmed a role for MyD88 and NF B in
mediating the HRPII effect. Triplotide has been show to decrease expression of NFкB/p65 and
increase expression of the cytosolic inhibitor IкB-α (Zeng et al., 2011; Zhu et al., 2009) Celastrol
has been shown to decrease expression and translocation of NFкB/p65 to the nucleus as well as
to diminish cleavage and activation of IкB-α (Ni et al., 2014; Yang et al., 2006). In the presence
of these inhibitors we observed a significantly decreased drop in TEER from HRPII. However,
we did not identify an upstream pathogen recognition receptor. Rather, additional studies
suggested involvement of the IL-1 receptor, as we could block HRPII-mediated barrier
disruption with IL-1Ra, a natural antagonist, or with antibody to IL-1β. IL-1β is a cytokine that is
activated from its pro-form by caspase-1. Caspase-1 is auto-catalytically processed when
molecules are brought in proximity by the inflammasome. Consistent with a key role for the
inflammasome the HRPII effect on TEER also was abolished by silencing of caspase-1 or
treatment of brain microvascular endothelial cells with a caspase-1 inhibitor.
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Inflammasome activation has been implicated in malaria infections previously.
Opsonization of parasitized red blood cells as well as pooled patient sera from P. falciparum
infections was shown to activate the inflammasome in macrophages (Zhou et al., 2012). IL-1β
has also been seen in histopathological sections from patients who died from cerebral malaria
(Armah et al., 2005; Udomsangpetch et al., 1997).
The data suggest a model for HRPII action on endothelial cells (Fig 2.13). HRPII
accumulates in the bloodstream and binds to vascular endothelium via an unknown receptor.
Downstream signaling allows for recruitment of inflammasome components, which activate
caspase-1 resulting in cleavage of substrates including pro-IL-1β, yielding mature IL-1β. Active
IL-1β is secreted, where it can bind to cell surface receptor IL-1R. IL-1R ligation transmits a
MyD88-dependent signal that activates the transcription factor NF B. NFĸB translocates to the
nucleus and induces transcription of many genes including cytoskeletal components, which can
redistribute tight and adherens junction proteins (Al-Sadi et al., 2009; Al-Sadi et al., 2012; AlSadi et al., 2010; Al-Sadi and Ma, 2007; Baumgartner et al., 2003; de Rivero Vaccari et al.,
2014; Kimura et al., 2009; Sollberger et al., 2014). Although there have been reports of tight
junction rearrangement via an NFĸB-independent pathway (Zhu et al., 2012), we believe HRPII
does not trigger this route as shRNA-mediated knockdown of NFĸB significantly inhibited
HRPII-mediated barrier compromise.
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Figure 2.13] Model for HRPII recognition by human brain endothelial cells and the
intracellular pathway that leads to BBB leakage. (1) HRPII binds to a yet unidentified
receptor (1) and is internalized (2). Inflammasome adaptor proteins associate with this endosome
(3) and recruit procaspase-1, which is auto-catalytically activated (4). Active caspase-1 can
cleave pro-IL-1 and pro-IL-18 into their mature forms (5). Mature IL-1β is secreted (6), such that
it can now bind to the IL-1 receptor, IL-1R (7). Signaling through MyD88, the IL-1R activates
NFĸB (8) as does downstream signaling from the inflammasome (9). NFĸB mediates
transcription of inflammatory genes (10), including those effecting redistribution of tight and
adherens junction proteins (11), resulting in a compromised blood brain barrier.

HRPII was active in vivo, resulting in BBB leakage as well as an exacerbation of
experimental CM when the protein was infused prior to infection or produced by transgenic
rodent malaria parasites. Aspects of HRPII action help explain some differences between the
pathophysiology seen in human CM and the experimental CM model. For example, tight
junction protein redistribution is not observed in eCM, suggesting that vascular leakage in the
rodent model occurs via an alternate mechanism than that observed in human pathology
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(Mukhopadhyay and Gordon, 2004; Nacer et al., 2014). HRPII-mediated barrier compromise
depends on caspase-1 activation of IL-1β, and IL-1β levels in the cerebrospinal fluid of patients
correlates with disease severity (John et al., 2008) while it has been shown to be dispensable for
the experimental CM model (Kordes et al., 2011). We propose that HRPII makes the P. berghei
system more falciparum-like; our data suggests that this protein may be a significant contributor
to human cerebral malaria. Directly targeting HRPII may prove to be therapeutic. Attempts in
the 1980s to use HRPII in Aotus monkey vaccination trials were encouraging, but follow up
studies were equivocal (Enders et al., 1992; Knapp et al., 1992; Knapp et al., 1988; Kocken et
al., 1998). Perhaps new studies informed by the proposed role in cerebral malaria could lead to
development of a vaccine that prevents CM. It may also be practical to prevent the outcomes of
HRPII by targeting upstream components of the pathway. Drugs targeting caspase-1 and IL-1 β
are already in clinical use, and may be efficacious in cerebral malaria.
Since causing CM is not likely to benefit the parasite, the question of why P. falciparum has
evolved and maintained the HRPII gene is germane. One possible advantage for the parasite is
that triggering an inflammatory pathway leads to upregulation of cytoadherence molecules on the
endothelial surface. Cytoadherence allows the parasite to avoid clearance in the spleen and reside
in a low-oxygen, high carbon dioxide environment. Parasite sequestration in the cerebral
vasculature is hallmark feature of human CM and one that is largely absent in the murine
experimental CM model. Other cytokines that are elevated in malaria such as TNF-

also

upregulate surface adhesion molecules that are receptors for malaria (Tchinda et al., 2007;
Turner et al., 1998).
Several new questions arise from this work: What does HRPII bind to initiate the inflammatory
process? Is HRPII synergistic with other P. falciparum virulence factors such as
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glycosylphosphatidylinositol (Schofield et al., 2002). Does HRPII affect endothelium in other
vascular beds in a similar manner? While our data strongly suggest that HRPII contributes to
malaria pathogenesis by modulating the BBB, further mechanistic insight is needed to develop
novel HRPII-dependent pharmacological strategies for disease control.
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2.5 Materials and Methods

Reagents
Bovine serum albumin (BSA), reagent grade was purchased from Sigma. Lipopolysaccharide
(LPS) from Escherichia coli O111:B4 was purchased from List Biologicals (catalog #201).
Antibodies
For confocal microscopy the following antibodies were used. Mouse αHRPII (2G12), a generous
gift from Diane Taylor, was used at 1:100 dilution. Rabbit α-zona-occludin-1 from Invitrogen
(40-2200) was used at 1:500 dilution. Goat anti-claudin-5 from Santa Cruz (sc-17667) was used
at 1:100. VE-cadherin (Santa Cruz, sc-52751) was used at 1:100. 5 µg of anti-HRPII for
neutralization for the TEER assays was purchased from Thermo Scientific (MA1-27094) while
the isotype control was generated as described (Pal et al., 2013). Rabbit anti-IL-1β for
neutralization in the TEER assay was from Rockland Immunochemical (209-401-301). Rabbit
anti-caspase-1 for western blotting (Novus, NBP1-45433) was used at a 1:333 dilution. Rabbit
anti-GAPDH (Abcam, ab37168) was used at 1:1000. Mouse anti-ICAM-1, -VCAM-1 and -Eselectin (BD Biosciences, 555510, 555645, and 555648) were used at 1:500, 1:100 and 1:500
dilutions, respectively. Armenian hamster anti-IL-1β for neutralization in vivo was purchased
from Leinco and used at 300 µg/mouse one day before infusion of protein.
Inhibitors
Triplotide from Invivogen was resuspended at 10 mM in DMSO and used at a final
concentration of 100 nM. Celastrol from Invivogen was resuspended at 4.4 mM in DMSO and
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used at a final concentration of 8.8 µM. IL1Ra from Sigma was resuspended in water and used at
a final concentration of 500 ng/mL. Caspase-1 inhibitor from Sigma (SML0429) was used at a
final concentration of 80 µM.
HRPII Purification
The coding sequence for the mature form of HRPII (Chang et al., 2008) was PCR amplified from
P. falciparum reverse-transcribed cellular RNA. The gene was cloned into a pET-15b vector
(Novagen) without a tag. The vector was transformed into BL21(DE3) cells and HRPII
production was induced using 0.4 mM IPTG at 16°C when the OD600 was between 0.6 and 0.8.
HRPII was purified from E. coli lysate using batch nickel bead (Pierce, 88222) purification with
a 250 mM imidazole wash and 1M imidazole elution in 20mM Tris, 500mM NaCl, pH 8.0.
Following this, HRPII was exchanged into nickel column loading buffer (20 mM Tris, 500 mM
NaCl and 50 mM imidazole) and loaded on a 5 ml nickel FPLC column (GE Healthcare, 175248-02). Column-bound HRPII was then washed with 60 column volumes of Triton X-114
wash buffer (20 mM Tris, 10 mM NaCl and 0.1% Triton X-114) to remove any residual LPS.
Protein was washed subsequently on the column with 20 column volumes of loading buffer and
then eluted with 1M imidazole buffer. All preparations of HRPII were tested for residual LPS
levels using the commercially available LAL endotoxin test (Charles Rivers, R1708K); levels
administered to mice were always less than 5EU/kg. Clean, fully active preparations of the
protein were used for in vitro and in vivo experiments. Activity was measured using the Factor
Xa assay developed previously (Ndonwi et al., 2011). Protein concentration was determined by
BCA assay (Fisher, P123227).
P. falciparum culture and transfection
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HRPII was PCR amplified from genomic DNA from 3D7 parasites and cloned into the TOPO
vector (Life Technologies). HRPII was inserted upstream of GFP in the tEOE vector under
control of the Hsp86 promoter. This vector is a modified form of the tyEOE vector with the
selectable marker human dihydrofolate reductase replacing the yeast dihydroorotate
dehydrogenase selection cassette (Beck et al., 2014). For transfection, 160 μl of a 50%
hematocrit RBC stock was electroporated with 100 μg of purified vector DNA and 50 µg of the
transposon vector MRA912 and then infected with 3D7 schizonts (Balu et al., 2005). After 72–
90 h, 10 nM WR99210 was added to the medium for drug selection and plasmid maintainence.
Parasites were grown under selective pressure for four weeks and then cloned out in a 96 well
plate at 0.5 parasites/ well. Clones were screened by PCR.
In vitro BBB Cultures and TEER recordings
In vitro BBB cultures were prepared as previously described (Daniels et al., 2013). Briefly, 105
hCMEC/D3 cells (Weksler et al., 2005) were cultured on the apical side of a 0.9 cm2 fibronectincoated polyethylene terephthalate filter insert with 3.0 μm porosity (BD Falcon) for 4 to 6 days
in supplemented endothelial basal medium with 1 ml in the upper chamber and 1.5 ml in the
lower chamber. Components for assessment (protein, chemical inhibitors, and parasitized
erythrocytes) were added to the apical chamber immediately after determining baseline values
for each well. Resistance recordings were measured via chopstick electrode with an EVOM
voltmeter (World Precision Instruments). Resistance values are reported as Ω/cm2 (recorded
values minus values for cell-free inserts).
shRNA knockdown and TEER
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105 hCMEC/D3 cells were cultured on the apical side of a 0.9 cm2 fibronectin-coated
polyethylene terephthalate filter insert with 3.0 μm porosity (BD Falcon). Twenty-four hours
later cells were transfected with 500 ng of shRNA with Lipofectamine 3000 at a 1.5:1 ratio of
Lipofectamine to DNA. Cells were then incubated for 36 hours. At that time, fresh warm
medium was added and then allowed to equilibrate for 30 minutes prior to taking baseline TEER
measurements. HRPII was then added and TEER measurements recorded over 24 hours.
shRNAs for each gene were purchased from Origene : Myd88 (TG311320), NFкB (TR318700),
Caspase-1 (TG305640), TLR9 (TR301076), TLR5 (TR308792), TLR2 (TR320553); of the four
shRNAs received from the vendor, 2-3 were used based on silencing efficiency in pilot studies.
One additional shRNA was used for MyD88 from Invivogen (ksirna42-hmyd88). All gene
silencing was performed using Lipofectamine 3000 at a ratio of 1.5: 1. Silencing efficiency for
all assays was determined by qRT-PCR.
Quantitative RT-PCR
Total RNA was isolated from treated or untreated cultured hCMEC/d3 cells by using the RNeasy
kit according to the manufacturer's instructions (Qiagen, http://www.qiagen.com/). During the
isolation, to remove any contaminating DNA, samples were treated with RNAse-free DNAse
(Qiagen). mRNA was quantified from total RNA by qRT-PCR as previously described (Samuel
and Diamond, 2005). PrimeTime qPCR primers and probes were purchased from IDT and used
to amplify human IL-1β, IL-6, CCL5, IFNα, IFN-β, Myd88, TLR-2, TLR-5, TLR-9, NFĸB, and
caspase-1 mRNA using the following assay IDs: IL-1β, Hs.PT.58.1518186; IL-6,
Hs.PT.58.39866843.g; CCL5, Hs.PT.58.1724551; IFN-β, Hs.PT.58.39481063.g; IFN-α,
Hs.PT.58.46311748.g; GAPDH, Hs.PT.39a.22214836; Myd88, Hs.PT.58.40601199.gs; TLR-2,
Hs.PT.58.21312907;

TLR-5,

Hs.PT.58.38446229;
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TLR-9,

Hs.PT.58.40576968;

NFĸB,

Hs.PT.58.892624; caspase-1, Hs.PT.56a.39122258.g. To analyze the relative fold induction of
amplified mRNA, GAPDH mRNA expression levels also were determined and normalization
was performed using the Ct method as described previously (Samuel and Diamond, 2005).

Mouse Model for Cerebral Malaria
Four week-old female mice C57BL6 were purchased from Taconic. Animals were housed under
pathogen-free conditions. All experiments were approved by and performed in compliance with
Animal Studies guidelines at Washington University in St Louis. Mice were given intravenous
retro-orbital injections of 50 µg of HRPII or BSA, in 100 µl of PBS approximately 12 hours
prior to infection while under anesthesia. The mice were then anesthetized again for intravenous
inoculation of P. berghei ANKA parasites (105 parasites in 100 µl) via retro-orbital injection
Parasitemia of stock mice for making the infection cocktail was determined by blood smear by
manually counting at least 2,000 cells; stock mice were used with parasitemias below 3%.
Transgenic P. berghei
Passage 2 P. berghei ANKA parasites were purified from 5 mice at close to 1% parasitemia by
collecting blood via intracardiac puncture. In vitro schizonts were generated by incubating in a
shaking (65 x rpm) gassed chamber at 5% CO2, 5% O2 and 90% N2 at 37⁰C in RPMI, 20% FCS
with gentamicin. Next day maturation of schizonts was confirmed by blood smear and schizonts
were purified across four 50 mL tubes filled with 35 mL of culture. This was done by placing a
10 mL 55% Histodenz column under each and spinning tubes at 200 g with no brake for 25
minutes; the schizont layers were pooled. 5 x107 purified schizonts were transfected with 10 µg
of pL1694 (Annoura et al., 2014) + HRPII-GFP linearized with Bcl1 and Sap1 in 100 µl of
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Nucleofector solution using an Amaxa Nucleofector on program U-033. Transfected parasites
were injected immediately via tail vein injection into 6-8 week old female Swiss Webster mice.
Mice were treated with pyrimethamine in their drinking water at 7 mg/mL starting the next day
for 1 week to select for integrants. Blood was collected from mice via cardiac puncture and
frozen. Single clones of transfected parasites were generated by infection of 20 mice at 1
parasite/mouse, and mice were screened by PCR for correct genetic manipulation.
TOPT-TA Cloning and sequence confirmation of transgenic P. berghei clone
Genomic DNA was purified from whole blood from an infected Swiss Webster Mouse at ~5%
parasitemia using the Quiagen Genomic DNA kits (51106) as described. The fragment between
230p 1455 and 5527 was PCR amplified using the Pfu Polymerase (Agilent Tech, 600380) as
described in the manufacturer’s instructions. The PCR-amplified product was TA cloned into the
TOPO vector as described in the manufacturer’s instructions (Life Technologies, 450030) and
the sequence verified.
In vivo assessment of BBB permeability
Two intravenous injections of HRPII (200 µg in 100 ul) were given 24 hours apart by retro
orbital injection to 4 week old female C57BL/6J mice from Jackson Labs. 48 hours post initial
injection, the mice were injected IP with 100 ul of 100 mg/ml of sodium fluorescein salt (SigmaAldrich) in sterile PBS. After 45 minutes, mice underwent extensive cardiac perfusion with PBS,
followed by collection of blood and harvesting of CNS tissues. Tissue homogenates and serum
were incubated overnight at 4°C at 1:1 dilution in 2% trichloroacetic acid (Sigma-Aldrich) to
precipitate protein, which was pelleted by 10 minute centrifugation at 16,100 x g at 4°C.
Supernatants were diluted in equal volumes of borate buffer, pH 11 (Sigma-Aldrich).
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Fluorescence emission at 538 nm was determined via a microplate reader using Synergy™ H1
and Gen5™ software (BioTek Instruments, Inc.). Tissue fluorescence values were standardized
against plasma values for individual mice. In some mice, anti-IL-1β antibody or isotype control
(300 ug each) were administered on day one before HRPII infusion.
Immunocytochemical and immunohistochemical analysis
Immunocytochemical analysis on hCMEC/d3 or Caco-2 cells was performed after 10 minute
fixation in ice-cold methanol, followed by blocking for 1 hour in 3% BSA in PBS at RT. Cells
were then incubated with primary antibodies to ZO-1, claudin-5, and VE-cadherin in blocking
buffer for 1 hour at RT, washed 3x in PBS, then incubated for one hour in secondary
AlexaFluor antibodies in blocking buffer at RT. Slides were washed extensively, followed by
staining with TOPRO at 1:500. Sections were sealed with ProLong Gold antifade and then
images acquired by confocal microscopy (Carl Zeiss USA).
TUNEL staining
Terminal deoxynucleotidyl transferase–mediated BrdUTP nick end labeling using TUNEL assay
kit (Roche, 12156792910) was performed on paraformaldehyde-fixed hCMEC/d3 cells that had
been treated with 25 μg HRPII, control protein or 3 μg LPS for 24 hours, as indicated in the
manufacturer’s instructions.
HRPII ELISA for quantification
HRPII was quantified in mouse sera using an ELISA as previously described (Gitau et al., 2013).

Acknowledgements

62

We thank Diane Taylor (University of Hawaii) for the 2G12 anti-HRPII antibody, Helen Lazear
and Jennifer Govero (Washington University) for help with experiments, Phil Miller for
statistical advice and Wayne Yokoyama (Washington University) for experimental advice.

63

2.6 References
Al-Sadi, R., Boivin, M., and Ma, T. (2009). Mechanism of cytokine modulation of epithelial
tight junction barrier. Frontiers in bioscience 14, 2765-2778.
Al-Sadi, R., Guo, S., Dokladny, K., Smith, M.A., Ye, D., Kaza, A., Watterson, D.M., and Ma,
T.Y. (2012). Mechanism of interleukin-1beta induced-increase in mouse intestinal permeability
in vivo. Journal of interferon & cytokine research : the official journal of the International
Society for Interferon and Cytokine Research 32, 474-484.
Al-Sadi, R., Ye, D., Said, H.M., and Ma, T.Y. (2010). IL-1beta-induced increase in intestinal
epithelial tight junction permeability is mediated by MEKK-1 activation of canonical NFkappaB pathway. The American journal of pathology 177, 2310-2322.
Al-Sadi, R.M., and Ma, T.Y. (2007). IL-1beta causes an increase in intestinal epithelial tight
junction permeability. Journal of immunology 178, 4641-4649.
Annoura, T., van Schaijk, B.C., Ploemen, I.H., Sajid, M., Lin, J.W., Vos, M.W., Dinmohamed,
A.G., Inaoka, D.K., Rijpma, S.R., van Gemert, G.J., et al. (2014). Two Plasmodium 6-Cys
family-related proteins have distinct and critical roles in liver-stage development. FASEB journal
: official publication of the Federation of American Societies for Experimental Biology 28, 21582170.
Armah, H., Dodoo, A.K., Wiredu, E.K., Stiles, J.K., Adjei, A.A., Gyasi, R.K., and Tettey, Y.
(2005). High-level cerebellar expression of cytokines and adhesion molecules in fatal, paediatric,
cerebral malaria. Annals of tropical medicine and parasitology 99, 629-647.
Balu, B., Shoue, D.A., Fraser, M.J., Jr., and Adams, J.H. (2005). High-efficiency transformation
of Plasmodium falciparum by the lepidopteran transposable element piggyBac. Proceedings of
the National Academy of Sciences of the United States of America 102, 16391-16396.
Baumgartner, W., Schutz, G.J., Wiegand, J., Golenhofen, N., and Drenckhahn, D. (2003).
Cadherin function probed by laser tweezer and single molecule fluorescence in vascular
endothelial cells. Journal of cell science 116, 1001-1011.
Beck, J.R., Muralidharan, V., Oksman, A., and Goldberg, D.E. (2014). PTEX component
HSP101 mediates export of diverse malaria effectors into host erythrocytes. Nature 511, 592595.
Benedetti, C.E., Kobarg, J., Pertinhez, T.A., Gatti, R.M., de Souza, O.N., Spisni, A., and
Meneghini, R. (2003). Plasmodium falciparum histidine-rich protein II binds to actin,
phosphatidylinositol 4,5-bisphosphate and erythrocyte ghosts in a pH-dependent manner and
undergoes coil-to-helix transitions in anionic micelles. Molecular and biochemical parasitology
128, 157-166.
Brewster, D.R., Kwiatkowski, D., and White, N.J. (1990). Neurological sequelae of cerebral
malaria in children. Lancet 336, 1039-1043.
Chang, H.H., Falick, A.M., Carlton, P.M., Sedat, J.W., DeRisi, J.L., and Marletta, M.A. (2008).
N-terminal processing of proteins exported by malaria parasites. Molecular and biochemical
parasitology 160, 107-115.
Chiodini, P.L., Bowers, K., Jorgensen, P., Barnwell, J.W., Grady, K.K., Luchavez, J., Moody,
A.H., Cenizal, A., and Bell, D. (2007). The heat stability of Plasmodium lactate dehydrogenasebased and histidine-rich protein 2-based malaria rapid diagnostic tests. Transactions of the Royal
Society of Tropical Medicine and Hygiene 101, 331-337.
64

Choi, C.Y., Cerda, J.F., Chu, H.A., Babcock, G.T., and Marletta, M.A. (1999). Spectroscopic
characterization of the heme-binding sites in Plasmodium falciparum histidine-rich protein 2.
Biochemistry 38, 16916-16924.
Craig, A.G., Grau, G.E., Janse, C., Kazura, J.W., Milner, D., Barnwell, J.W., Turner, G.,
Langhorne, J., and participants of the Hinxton Retreat meeting on Animal Models for Research
on Severe, M. (2012). The role of animal models for research on severe malaria. PLoS pathogens
8, e1002401.
Daniels, B.P., Cruz-Orengo, L., Pasieka, T.J., Couraud, P.O., Romero, I.A., Weksler, B., Cooper,
J.A., Doering, T.L., and Klein, R.S. (2013). Immortalized human cerebral microvascular
endothelial cells maintain the properties of primary cells in an in vitro model of immune
migration across the blood brain barrier. Journal of neuroscience methods 212, 173-179.
Das, P., Grewal, J.S., and Chauhan, V.S. (2006). Interaction of Plasmodium falciparum histidinerich protein II with human lymphocytes leads to suppression of proliferation, IFN-gamma
release, and CD69 expression. Parasitology research 100, 39-50.
de Oca, M.M., Engwerda, C., and Haque, A. (2013). Plasmodium berghei ANKA (PbA)
infection of C57BL/6J mice: a model of severe malaria. Methods in molecular biology 1031,
203-213.
de Rivero Vaccari, J.P., Dietrich, W.D., and Keane, R.W. (2014). Activation and regulation of
cellular inflammasomes: gaps in our knowledge for central nervous system injury. Journal of
cerebral blood flow and metabolism : official journal of the International Society of Cerebral
Blood Flow and Metabolism 34, 369-375.
de Souza, J.B., Hafalla, J.C., Riley, E.M., and Couper, K.N. (2010). Cerebral malaria: why
experimental murine models are required to understand the pathogenesis of disease. Parasitology
137, 755-772.
de Souza, J.B., and Riley, E.M. (2002). Cerebral malaria: the contribution of studies in animal
models to our understanding of immunopathogenesis. Microbes and infection / Institut Pasteur 4,
291-300.
Desakorn, V., Dondorp, A.M., Silamut, K., Pongtavornpinyo, W., Sahassananda, D.,
Chotivanich, K., Pitisuttithum, P., Smithyman, A.M., Day, N.P., and White, N.J. (2005). Stagedependent production and release of histidine-rich protein 2 by Plasmodium falciparum.
Transactions of the Royal Society of Tropical Medicine and Hygiene 99, 517-524.
Dondorp, A.M., Desakorn, V., Pongtavornpinyo, W., Sahassananda, D., Silamut, K.,
Chotivanich, K., Newton, P.N., Pitisuttithum, P., Smithyman, A.M., White, N.J., et al. (2005).
Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS
medicine 2, e204.
Enders, B., Hundt, E., and Knapp, B. (1992). Protection of Aotus monkeys after immunization
with recombinant antigens of Plasmodium falciparum. Memorias do Instituto Oswaldo Cruz 87
Suppl 3, 413-422.
Engwerda, C., Belnoue, E., Gruner, A.C., and Renia, L. (2005). Experimental models of cerebral
malaria. Current topics in microbiology and immunology 297, 103-143.
Fernando, S.D., Rodrigo, C., and Rajapakse, S. (2010). The 'hidden' burden of malaria: cognitive
impairment following infection. Malaria journal 9, 366.
Fox, L.L., Taylor, T.E., Pensulo, P., Liomba, A., Mpakiza, A., Varela, A., Glover, S.J., Reeves,
M.J., and Seydel, K.B. (2013). Histidine-rich protein 2 plasma levels predict progression to
cerebral malaria in Malawian children with Plasmodium falciparum infection. The Journal of
infectious diseases 208, 500-503.
65

Gamboa, D., Ho, M.F., Bendezu, J., Torres, K., Chiodini, P.L., Barnwell, J.W., Incardona, S.,
Perkins, M., Bell, D., McCarthy, J., et al. (2010). A large proportion of P. falciparum isolates in
the Amazon region of Peru lack pfhrp2 and pfhrp3: implications for malaria rapid diagnostic
tests. PloS one 5, e8091.
Gitau, E.N., Kokwaro, G.O., Karanja, H., Newton, C.R., and Ward, S.A. (2013). Plasma and
cerebrospinal proteomes from children with cerebral malaria differ from those of children with
other encephalopathies. The Journal of infectious diseases 208, 1494-1503.
Hawkes, M., Elphinstone, R.E., Conroy, A.L., and Kain, K.C. (2013). Contrasting pediatric and
adult cerebral malaria: the role of the endothelial barrier. Virulence 4, 543-555.
Hendriksen, I.C., Mwanga-Amumpaire, J., von Seidlein, L., Mtove, G., White, L.J.,
Olaosebikan, R., Lee, S.J., Tshefu, A.K., Woodrow, C., Amos, B., et al. (2012). Diagnosing
severe falciparum malaria in parasitaemic African children: a prospective evaluation of plasma
PfHRP2 measurement. PLoS medicine 9, e1001297.
Hendriksen, I.C., White, L.J., Veenemans, J., Mtove, G., Woodrow, C., Amos, B., Saiwaew, S.,
Gesase, S., Nadjm, B., Silamut, K., et al. (2013). Defining falciparum-malaria-attributable severe
febrile illness in moderate-to-high transmission settings on the basis of plasma PfHRP2
concentration. The Journal of infectious diseases 207, 351-361.
Howard, R.J., Uni, S., Aikawa, M., Aley, S.B., Leech, J.H., Lew, A.M., Wellems, T.E., Rener, J.,
and Taylor, D.W. (1986). Secretion of a malarial histidine-rich protein (Pf HRP II) from
Plasmodium falciparum-infected erythrocytes. The Journal of cell biology 103, 1269-1277.
Idro, R., Jenkins, N.E., and Newton, C.R. (2005). Pathogenesis, clinical features, and
neurological outcome of cerebral malaria. The Lancet Neurology 4, 827-840.
Idro, R., Kakooza-Mwesige, A., Balyejjussa, S., Mirembe, G., Mugasha, C., Tugumisirize, J.,
and Byarugaba, J. (2010). Severe neurological sequelae and behaviour problems after cerebral
malaria in Ugandan children. BMC research notes 3, 104.
John, C.C., Panoskaltsis-Mortari, A., Opoka, R.O., Park, G.S., Orchard, P.J., Jurek, A.M., Idro,
R., Byarugaba, J., and Boivin, M.J. (2008). Cerebrospinal fluid cytokine levels and cognitive
impairment in cerebral malaria. The American journal of tropical medicine and hygiene 78, 198205.
Kawai, T., and Akira, S. (2005). Pathogen recognition with Toll-like receptors. Current opinion
in immunology 17, 338-344.
Kawai, T., and Akira, S. (2010). The role of pattern-recognition receptors in innate immunity:
update on Toll-like receptors. Nature immunology 11, 373-384.
Kimura, K., Teranishi, S., and Nishida, T. (2009). Interleukin-1beta-induced disruption of barrier
function in cultured human corneal epithelial cells. Investigative ophthalmology & visual science
50, 597-603.
Knapp, B., Hundt, E., Enders, B., and Kupper, H.A. (1992). Protection of Aotus monkeys from
malaria infection by immunization with recombinant hybrid proteins. Infection and immunity 60,
2397-2401.
Knapp, B., Shaw, A., Hundt, E., Enders, B., and Kupper, H.A. (1988). A histidin alanine rich
recombinant antigen protects Aotus monkeys from P. falciparum infection. Behring Institute
Mitteilungen, 349-359.
Kocken, C.H., Hundt, E., Knapp, B., Brazel, D., Enders, B., Narum, D.L., Wubben, J.A., and
Thomas, A.W. (1998). Immunization of Aotus monkeys with recombinant Plasmodium
falciparum hybrid proteins does not reproducibly result in protection from malaria infection.
Infection and immunity 66, 373-375.
66

Koita, O.A., Doumbo, O.K., Ouattara, A., Tall, L.K., Konare, A., Diakite, M., Diallo, M.,
Sagara, I., Masinde, G.L., Doumbo, S.N., et al. (2012). False-negative rapid diagnostic tests for
malaria and deletion of the histidine-rich repeat region of the hrp2 gene. The American journal of
tropical medicine and hygiene 86, 194-198.
Kordes, M., Matuschewski, K., and Hafalla, J.C. (2011). Caspase-1 activation of interleukin1beta (IL-1beta) and IL-18 is dispensable for induction of experimental cerebral malaria.
Infection and immunity 79, 3633-3641.
Kumar, N., Pande, V., Bhatt, R.M., Shah, N.K., Mishra, N., Srivastava, B., Valecha, N., and
Anvikar, A.R. (2013). Genetic deletion of HRP2 and HRP3 in Indian Plasmodium falciparum
population and false negative malaria rapid diagnostic test. Acta tropica 125, 119-121.
Lawrence, T. (2009). The nuclear factor NF-kappaB pathway in inflammation. Cold Spring
Harbor perspectives in biology 1, a001651.
MacPherson, G.G., Warrell, M.J., White, N.J., Looareesuwan, S., and Warrell, D.A. (1985).
Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte
sequestration. The American journal of pathology 119, 385-401.
Madkhali, A.M., Alkurbi, M.O., Szestak, T., Bengtsson, A., Patil, P.R., Wu, Y., Alharthi, S.,
Jensen, A.T., Pleass, R., and Craig, A.G. (2014). An Analysis of the Binding Characteristics of a
Panel of Recently Selected ICAM-1 Binding Plasmodium falciparum Patient Isolates. PloS one
9, e111518.
Mashima, R., Tilley, L., Siomos, M.A., Papalexis, V., Raftery, M.J., and Stocker, R. (2002).
Plasmodium falciparum histidine-rich protein-2 (PfHRP2) modulates the redox activity of ferriprotoporphyrin IX (FePPIX): peroxidase-like activity of the PfHRP2-FePPIX complex. The
Journal of biological chemistry 277, 14514-14520.
Medana, I.M., Chaudhri, G., Chan-Ling, T., and Hunt, N.H. (2001). Central nervous system in
cerebral malaria: 'Innocent bystander' or active participant in the induction of immunopathology?
Immunology and cell biology 79, 101-120.
Menezes, R.G., Pant, S., Kharoshah, M.A., Senthilkumaran, S., Arun, M., Nagesh, K.R., Bhat,
N.B., Mahadeshwara Prasad, D.R., Karki, R.K., Subba, S.H., et al. (2012). Autopsy discoveries
of death from malaria. Legal medicine 14, 111-115.
Miller, L.H., Baruch, D.I., Marsh, K., and Doumbo, O.K. (2002). The pathogenic basis of
malaria. Nature 415, 673-679.
Moody, A. (2002). Rapid diagnostic tests for malaria parasites. Clinical microbiology reviews
15, 66-78.
Mukhopadhyay, S., and Gordon, S. (2004). The role of scavenger receptors in pathogen
recognition and innate immunity. Immunobiology 209, 39-49.
Nacer, A., Movila, A., Sohet, F., Girgis, N.M., Gundra, U.M., Loke, P., Daneman, R., and
Frevert, U. (2014). Experimental cerebral malaria pathogenesis-hemodynamics at the blood brain
barrier. PLoS pathogens 10, e1004528.
Ndonwi, M., Burlingame, O.O., Miller, A.S., Tollefsen, D.M., Broze, G.J., Jr., and Goldberg,
D.E. (2011). Inhibition of antithrombin by Plasmodium falciparum histidine-rich protein II.
Blood 117, 6347-6354.
Ni, H., Zhao, W., Kong, X., Li, H., and Ouyang, J. (2014). NF-kappa B modulation is involved
in celastrol induced human multiple myeloma cell apoptosis. PloS one 9, e95846.
Pal, P., Dowd, K.A., Brien, J.D., Edeling, M.A., Gorlatov, S., Johnson, S., Lee, I., Akahata, W.,
Nabel, G.J., Richter, M.K., et al. (2013). Development of a highly protective combination
monoclonal antibody therapy against Chikungunya virus. PLoS pathogens 9, e1003312.
67

Parra, M.E., Evans, C.B., and Taylor, D.W. (1991). Identification of Plasmodium falciparum
histidine-rich protein 2 in the plasma of humans with malaria. Journal of clinical microbiology
29, 1629-1634.
Pongponratn, E., Turner, G.D., Day, N.P., Phu, N.H., Simpson, J.A., Stepniewska, K., Mai, N.T.,
Viriyavejakul, P., Looareesuwan, S., Hien, T.T., et al. (2003). An ultrastructural study of the
brain in fatal Plasmodium falciparum malaria. The American journal of tropical medicine and
hygiene 69, 345-359.
Riley, E.M., Couper, K.N., Helmby, H., Hafalla, J.C., de Souza, J.B., Langhorne, J., Jarra, W.B.,
and Zavala, F. (2010). Neuropathogenesis of human and murine malaria. Trends in parasitology
26, 277-278.
Rock, E.P., Marsh, K., Saul, A.J., Wellems, T.E., Taylor, D.W., Maloy, W.L., and Howard, R.J.
(1987). Comparative analysis of the Plasmodium falciparum histidine-rich proteins HRP-I, HRPII and HRP-III in malaria parasites of diverse origin. Parasitology 95 ( Pt 2), 209-227.
Samuel, M.A., and Diamond, M.S. (2005). Alpha/beta interferon protects against lethal West
Nile virus infection by restricting cellular tropism and enhancing neuronal survival. Journal of
virology 79, 13350-13361.
Schofield, L., Hewitt, M.C., Evans, K., Siomos, M.A., and Seeberger, P.H. (2002). Synthetic
GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 418, 785-789.
Seydel, K.B., Fox, L.L., Glover, S.J., Reeves, M.J., Pensulo, P., Muiruri, A., Mpakiza, A.,
Molyneux, M.E., and Taylor, T.E. (2012). Plasma concentrations of parasite histidine-rich
protein 2 distinguish between retinopathy-positive and retinopathy-negative cerebral malaria in
Malawian children. The Journal of infectious diseases 206, 309-318.
Seydel, K.B., Kampondeni, S.D., Valim, C., Potchen, M.J., Milner, D.A., Muwalo, F.W.,
Birbeck, G.L., Bradley, W.G., Fox, L.L., Glover, S.J., et al. (2015). Brain swelling and death in
children with cerebral malaria. The New England journal of medicine 372, 1126-1137.
Sollberger, G., Strittmatter, G.E., Garstkiewicz, M., Sand, J., and Beer, H.D. (2014). Caspase-1:
the inflammasome and beyond. Innate immunity 20, 115-125.
Storm, J., and Craig, A.G. (2014). Pathogenesis of cerebral malaria--inflammation and
cytoadherence. Frontiers in cellular and infection microbiology 4, 100.
Sullivan, D.J., Jr., Gluzman, I.Y., and Goldberg, D.E. (1996). Plasmodium hemozoin formation
mediated by histidine-rich proteins. Science 271, 219-222.
Tchinda, V.H., Tadem, A.D., Tako, E.A., Tene, G., Fogako, J., Nyonglema, P., Sama, G., Zhou,
A., and Leke, R.G. (2007). Severe malaria in Cameroonian children: correlation between plasma
levels of three soluble inducible adhesion molecules and TNF-alpha. Acta tropica 102, 20-28.
Tripathi, A.K., Sullivan, D.J., and Stins, M.F. (2007). Plasmodium falciparum-infected
erythrocytes decrease the integrity of human blood-brain barrier endothelial cell monolayers. The
Journal of infectious diseases 195, 942-950.
Turner, G.D., Ly, V.C., Nguyen, T.H., Tran, T.H., Nguyen, H.P., Bethell, D., Wyllie, S.,
Louwrier, K., Fox, S.B., Gatter, K.C., et al. (1998). Systemic endothelial activation occurs in
both mild and severe malaria. Correlating dermal microvascular endothelial cell phenotype and
soluble cell adhesion molecules with disease severity. The American journal of pathology 152,
1477-1487.
Udomsangpetch, R., Chivapat, S., Viriyavejakul, P., Riganti, M., Wilairatana, P., Pongponratin,
E., and Looareesuwan, S. (1997). Involvement of cytokines in the histopathology of cerebral
malaria. The American journal of tropical medicine and hygiene 57, 501-506.

68

Weksler, B.B., Subileau, E.A., Perriere, N., Charneau, P., Holloway, K., Leveque, M., TricoireLeignel, H., Nicotra, A., Bourdoulous, S., Turowski, P., et al. (2005). Blood-brain barrierspecific properties of a human adult brain endothelial cell line. FASEB journal : official
publication of the Federation of American Societies for Experimental Biology 19, 1872-1874.
Wellems, T.E., and Howard, R.J. (1986). Homologous genes encode two distinct histidine-rich
proteins in a cloned isolate of Plasmodium falciparum. Proceedings of the National Academy of
Sciences of the United States of America 83, 6065-6069.
White, N.J., Turner, G.D., Medana, I.M., Dondorp, A.M., and Day, N.P. (2010). The murine
cerebral malaria phenomenon. Trends in parasitology 26, 11-15.
Yang, H., Chen, D., Cui, Q.C., Yuan, X., and Dou, Q.P. (2006). Celastrol, a triterpene extracted
from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human
prostate cancer growth in nude mice. Cancer research 66, 4758-4765.
Zeng, R., Zeng, L., Chen, Y., Zhao, F., Li, R., Wen, L., and Zhang, C. (2011). Triptolide-induced
apoptosis by inactivating nuclear factor-kappa B apoptotic pathway in multiple myeloma in
vitro. Journal of Huazhong University of Science and Technology Medical sciences = Hua zhong
ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao Yixue Yingdewen
ban 31, 446-451.
Zhou, J., Ludlow, L.E., Hasang, W., Rogerson, S.J., and Jaworowski, A. (2012). Opsonization of
malaria-infected erythrocytes activates the inflammasome and enhances inflammatory cytokine
secretion by human macrophages. Malaria journal 11, 343.
Zhu, W., London, N.R., Gibson, C.C., Davis, C.T., Tong, Z., Sorensen, L.K., Shi, D.S., Guo, J.,
Smith, M.C., Grossmann, A.H., et al. (2012). Interleukin receptor activates a MYD88-ARNOARF6 cascade to disrupt vascular stability. Nature 492, 252-255.
Zhu, W., Ou, Y., Li, Y., Xiao, R., Shu, M., Zhou, Y., Xie, J., He, S., Qiu, P., and Yan, G. (2009).
A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid
carcinoma cells via down-regulation of the nuclear factor-kappa B pathway. Molecular
pharmacology 75, 812-819.

69

Chapter 3: Conclusions and Future
Directions

70

Cerebral malaria (CM) is a disease of the vascular endothelium caused by Plasmodium
falciparum. It is characterized by parasite sequestration, inflammatory cytokine production and
vascular leakage. A distinguishing feature of P. falciparum infection is parasite production and
secretion of histidine-rich protein II (HRPII). Plasma HRPII is a diagnostic and prognostic
marker for falciparum malaria. Using a human cerebral microvascular endothelial blood-brain
barrier model, we demonstrate that HRPII activates the inflammasome, resulting in redistribution
of tight junction proteins and compromise of barrier integrity. Intravenous administration of
HRPII induces vascular leakage in the brains of mice and increased early mortality in P. berghei
experimental cerebral malaria. Transgenic P. berghei expressing falciparum HRPII display
enhanced disease severity. HRPII induces endothelial expression of adhesion receptors,
suggesting that this protein also contributes to pathogenesis by enhancing parasite
cytoadherence. We propose that HRPII is a virulence factor that contributes to cerebral malaria
by compromising blood-brain barrier integrity and promoting parasite sequestration in the brain
microvasculature.
Toxic mediators have been known to be released during a P. falciparum infection (Clark and
Cowden, 2003; Schofield et al., 2002). Furthermore, addition of cultured P. falciparum parasites
to brain endothelial cells compromises barrier integrity, with parasites as well as with soluble
released components (Tripathi et al., 2007). Although many factors have been suspected as a
toxic mediator in P. falciparum infection, none have been convincingly shown. The studies
compromising this thesis provide a new framework for thinking about HRPII, a protein formerly
considered simply a diagnostic marker for Plasmodium sp. infection, to a toxic virulence factor.
We have worked backwards up the pathway and found that HRPII activates an inflammatory
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response in brain endothelial cells that is mediated by NFĸB and dependent on MyD88. The
pathway activates the inflammasome as it produces IL-1β and is caspase-1 dependent.
Having identified HRPII as a protein of interest there is a considerable amount of work to be
done if we want to target it therapeutically in the context of a malarial infection. First, it would
be enlightening to use the transgenic P. berghei ANKA lines to pursue further pathophysiological
studies in mice. Do the parasites that produce HRPII also cause a rearrangement of tight junction
proteins in the mouse brain, similar to that observed in human pathology or the human brain
endothelial cell in vitro studies? Do we see increased blood brain barrier leakage using
fluorescein as a vascular tracer when mice are infected with the transgenic parasites compared to
wild- type parasites? Will we observe an altered immune response with the transgenic parasites,
both in terms of the kind of cells activated as well as the kinetics of the response? Our in vitro
studies showed that there was an up-regulation of surface adhesion markers such as ICAM-1 and
VCAM-1 on the brain endothelial cells by flow cytometry. Does this increase in surface display
have functional relevance in terms of parasite adhesion to endothelial cell monolayers? This can
be tested by lateral flow of P. falciparum parasites on an HRPII activated endothelial cell
monolayers. Furthermore, does HRPII also cause increased surface display of ICAM-1 and
VCAM-1 on murine cerebral vasculatures? If so, do we see an increase in sequestered parasites
in the infected mouse vasculature?
In preliminary studies, we visualized small vesicles in the human brain endothelial cells staining
for HRPII, indicating that HRPII is internalized into the cell from the cell surface. How is the
protein internalized? Is internalization receptor-mediated? A schematic of where the receptor
would fit in our model is shown below in figure 3.1. If so, does this receptor also serve as the
molecular sensor for inflammasome activation? The molecular sensor that HRPII binds to
72

allowing association with the inflammasome is also not identified. Identification of the receptor
or the molecular sensor could be initiated with immunoprecipitation (IP). An IP done with the
correct conditions could identify such a protein. This interaction could be corroborated with
reciprocal IPs as well as knockdowns of the protein to see if functional consequence of HRPII
could be abrogated. If HRPII activity could be halted in the absence or reduction (from
knockdown) of the sensor/ receptor then a point of intervention could be identified. Early
evidence, via co-immunofluorescence, lead us to suspect that the thrombin receptor PAR-1 may
be this mystery receptor. In addition, knocking down the PAR-1 receptor with shRNAs also
reduced the drop in electrical resistance seen from HRPII. However, qPCRs of various proinflammatory cytokines and chemokines in the presence of a synthetic inhibitor of the PAR1receptor showed that suppression of the receptor is actually anti-inflammatory. Since our work
has identified that NFĸB is activated in the presence of HRPII, a nonspecific anti-inflammatory
event such as an inhibitor of PAR-1or knocking down PAR-1 mRNA by shRNA could
inadvertently prevent the blood brain barrier compromise we observe from HRPII, rather than
the effect being mediated by a specific event. However, further follow-up studies are needed to
make a conclusive call. If the PAR-1 receptor is not the receptor or molecular sensor, we will
continue to pursue optimizing conditions for immunoprecipitation to identify the molecule in
question.
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Figure 3.1] Model for HRPII recognition by human brain endothelial cells and the
intracellular pathway that leads to BBB leakage. (1) HRPII binds to a yet unconfirmed
receptor that may be the thrombin receptor PAR-1 (1) and is internalized (2). Inflammasome
adaptor proteins associate with this endosome (3) and recruit procaspase-1, which is autocatalytically activated (4). Active caspase-1 can cleave pro-IL-1 and pro-IL-18 into their mature
forms (5). Mature IL-1β is secreted (6), such that it can now bind to the IL-1 receptor, IL-1R (7).
Signaling through MyD88, the IL-1R activates NFĸB (8) as does downstream signaling from the
inflammasome (9). NFĸB mediates transcription of inflammatory genes (10), including those
effecting redistribution of tight and adherens junction proteins (11), resulting in a compromised
blood brain barrier.

It is of evolutionary intrigue to consider why a parasite would carry a protein that is toxic to its
host. Amongst the parasites that infect humans, HRPII is only present in P. falciparum, with no
homologous proteins in the other four parasite species. Is this because it was never in the genome
of other species, or was it lost because it was a disadvantageous to the parasite? Does HRPII
make P. falciparum the most virulent of the species? Some insight into these questions may be

74

provided by studying the homologous histidine rich proteins in Plasmodium species that infect
primates: P. reichenowi and P. gaboni. It would be fascinating to explore if these evolutionary
ancestors are functionally similar to the P. falciparum protein, particularly considering that these
are the only known homologs in any organism. To study this we have cloned these genes, and
have transfected them into a P. falciparum parasite line that does not have HRPII. Preliminary
TEER experiments with recombinant protein showed a small compromise in barrier integrity;
however these preparations were not clean from LPS. Protein preparations clean from LPS may
reveal limited compromise in barrier integrity considering that the impure batches shown small
differences. It will also be exciting to see what similar experiments with the parasite lines
containing primate HRPII will reveal. In addition we will perform growth curves with these are
the parasite lines producing HRPII in isogenic backgrounds to determine whether HRPII protein
production by the parasite shows any change in growth- either an advantage or disadvantage.
Pursuing these studies is sure to yield more burning questions. It will be exciting to see if the
future holds a place for therapeutics targeted at HRPII either the protein directly or a step in the
pathway of its activity. Directly targeting HRPII may prove to be therapeutic as it would reduce
many of the consequences of infection BBB leakage and parasite sequestration or eliminate them
if HRPII is the only protein that causes these effects. Attempts in the 1980s to use HRPII in
Aotus monkey vaccination trials were encouraging, but follow up studies were equivocal (Enders
et al., 1992; Knapp et al., 1992; Knapp et al., 1988; Kocken et al., 1998). Perhaps new studies
informed by the proposed role in cerebral malaria could lead to development of a vaccine that
prevents CM. It may also be practical to prevent the outcomes of HRPII by targeting upstream
components of the pathway. Drugs targeting caspase-1 and IL-1 β are already in clinical use, and
may be efficacious in cerebral malaria.
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